"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 3 | 6 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 4 | 5 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 3 | 8 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 3 | 5 |
| 2015 | 3 | 2 | 5 |
| 2016 | 6 | 2 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 6 | 6 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 2 | 3 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
Design, synthesis, and biological evaluation of Benzimidazole-Aminopyrimidine hybrids as selective P38a MAPK inhibitors targeting Neuroinflammation in an AlCl3-induced rat model of Alzheimer's disease. Bioorg Chem. 2026 Feb; 169:109391.
-
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. Neuro Oncol. 2025 May 15; 27(4):1092-1101.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
A retrospective analysis of the use of candesartan for migraine prevention in adolescents. Headache. 2024 01; 64(1):96-97.
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
-
A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0034923.